Company Overview
| Stock Name | Medbot-B |
|---|---|
| Stock Code | 02252 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 設計、開發及商業化手術機器人,以協助外科醫生完成複雜的外科手術。公司是全球行業中唯一一家擁有覆蓋五大主要及快速增長手術專科(即腔鏡、骨科、泛血管、經自然腔道及經皮穿刺手術)產品組合的公司。 |
| Listing Date | 2021-11-02 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市中國(上海)自由貿易試驗區張東路1601號1幢B區101室 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | medbotsurgical.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 43.20 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 21,600 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-10-21 to 2021-10-26 |
| Global Offering Shares | 36,200,000 shares |
| HK Public Offer Shares (Initial) | 3,620,000 shares (10.0%) |
| Public Offer Lots (Initial) | 7,240lots (Pool A3,620lots,Pool B3,620lots) |
| International Placing Shares (Initial) | 32,580,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 953,163,831 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 45.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,563,840,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 21,600 |
| 2 lots | 1,000 | HK$ 43,200 |
| 3 lots | 1,500 | HK$ 64,800 |
| 4 lots | 2,000 | HK$ 86,400 |
| 5 lots | 2,500 | HK$ 108,000 |
| 6 lots | 3,000 | HK$ 129,600 |
| 7 lots | 3,500 | HK$ 151,200 |
| 8 lots | 4,000 | HK$ 172,800 |
| 9 lots | 4,500 | HK$ 194,400 |
| 10 lots | 5,000 | HK$ 216,000 |
| 12 lots | 6,000 | HK$ 259,200 |
| 14 lots | 7,000 | HK$ 302,400 |
| 16 lots | 8,000 | HK$ 345,600 |
| 18 lots | 9,000 | HK$ 388,800 |
| 20 lots | 10,000 | HK$ 432,000 |
| 30 lots | 15,000 | HK$ 648,000 |
| 40 lots | 20,000 | HK$ 864,000 |
| 50 lots | 25,000 | HK$ 1,080,000 |
| 60 lots | 30,000 | HK$ 1,296,000 |
| 70 lots | 35,000 | HK$ 1,512,000 |
| 80 lots | 40,000 | HK$ 1,728,000 |
| 90 lots | 45,000 | HK$ 1,944,000 |
| 100 lots | 50,000 | HK$ 2,160,000 |
| 110 lots | 55,000 | HK$ 2,376,000 |
| 120 lots | 60,000 | HK$ 2,592,000 |
| 130 lots | 65,000 | HK$ 2,808,000 |
| 140 lots | 70,000 | HK$ 3,024,000 |
| 150 lots | 75,000 | HK$ 3,240,000 |
| 160 lots | 80,000 | HK$ 3,456,000 |
| 170 lots | 85,000 | HK$ 3,672,000 |
| 180 lots | 90,000 | HK$ 3,888,000 |
| 190 lots | 95,000 | HK$ 4,104,000 |
| 200 lots | 100,000 | HK$ 4,320,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 8,640,000 |
| 600 lots | 300,000 | HK$ 12,960,000 |
| 800 lots | 400,000 | HK$ 17,280,000 |
| 1,000 lots | 500,000 | HK$ 21,600,000 |
| 1,200 lots | 600,000 | HK$ 25,920,000 |
| 1,400 lots | 700,000 | HK$ 30,240,000 |
| 1,600 lots | 800,000 | HK$ 34,560,000 |
| 1,800 lots | 900,000 | HK$ 38,880,000 |
| 2,000 lots | 1,000,000 | HK$ 43,200,000 |
| 2,400 lots | 1,200,000 | HK$ 51,840,000 |
| 2,800 lots | 1,400,000 | HK$ 60,480,000 |
| 3,200 lots | 1,600,000 | HK$ 69,120,000 |
| 3,620 lots | 1,810,000 | HK$ 78,192,000 |
| 16,637 lots | 8,318,686 | HK$ 359,367,235 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 24.95B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 37,745,287,708 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 40,891,577,241 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣209.3百萬元 |
| Period-End Cash Balance | 人民幣1,497.3百萬元 |
| Listing Expenses | ~HK$ 101,220,000 |
| Listing Expenses / Funds Raised | ~6.47% |
| Total Pre-IPO Investment | 人民幣15億元 |
Financial Data
Unit:
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Profit for the year | -768 | -969 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 643 | 603 |
| Inventories | 0 | 0 |
| Total current assets | 601 | 899 |
| Total current liabilities | 927 | 921 |
| Total equity | 509 | 924 |
| Equity attributable to owners | 503 | 922 |
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 45.8 |
|---|---|
| First Day Open | HK$ 39.8 |
| First Day Change | 6.02% |
| First Day Volume | 21828600.0 |
| First Day Turnover | 960977000.0 |
| Use of Proceeds | 1、約510.1百萬港元(占35.0%)將用于我們的核心產品圖邁;
2、約306.1百萬港元(占21.0%)將用于我們的骨科手術機器人;
3、約276.9百萬港元(占19.0%)將用于我們其他候選產品;
4、約72.9百萬港元(占5.0%)將用于提高制造與供應鏈管理能力;
5、約145.7百萬港元(占10.0%)將用于擴大我們的產品組合;
6、約145.7百萬港元(占10.0%)將用作營運資金及一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (2)
Joint Bookrunners (2)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Artisan China Post-Venture Master Fund LP | 37,065,600 HKD | — | 2.40% | — | 6 months | 2022-05-02 |
| 2 | Aspex Master Fund | 148,154,400 HKD | — | 9.50% | — | 6 months | 2022-05-02 |
| 3 | CloudAlpha Master Fund | 74,066,400 HKD | — | 4.70% | — | 6 months | 2022-05-02 |
| 4 | Hillhouse Funds | 111,110,400 HKD | — | 7.10% | — | 6 months | 2022-05-02 |
| 5 | LAV Star Limited | 111,110,400 HKD | — | 7.10% | — | 6 months | 2022-05-02 |
| 6 | Snow Lake China Master Fund, Ltd. | 111,110,400 HKD | — | 7.10% | — | 6 months | 2022-05-02 |
| 7 | Yorkool International Limited | 111,110,400 HKD | — | 7.10% | — | 6 months | 2022-05-02 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 孫洪斌 | — |
| Company Secretary | 許燕珊 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東上海默化、上海擎禎、微創投資及微創醫療,緊隨全球發售完成後合共控制本公司股本總額約52.53%(不計超額配股權);何超博士及其配偶合計擁有約65.24%權益。 |
|---|




